FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Doroshow

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Ari VanderWalde; J Wong; W Ye; Przemyslaw Twardowski; D Asuncion; James Doroshow; Stephen Forman; Paul Frankel; Marianna Koczywas; Lucille Leong; T Luu; Kim Margolin; Robert Morgan; I B Paz; Richard D Pezner; Stephen Shibata; George Somlo
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
William C Reinhold; Margot Sunshine; Sudhir Varma; James Doroshow; Kurt W Kohn; Hongfang Liu; Joel Morris; Yves Pommier
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.
Shivaani Kummar; Heinz-Josef Lenz; Robert Morgan; Edward M Newman; Ralph E Parchment; Shannon L Puhalla; Larry Rubinstein; Joseph E Tomaszewski; Lihua Wang; Yiping Zhang; Deborah Allen; Chandra P Belani; Jan H Beumer; Alice Chen; David R Gandara; Jiuping Ji; Brian Kiesel; Robert Kinders; James Doroshow
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Doroshow (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ari VanderWalde; J Wong; W Ye; Przemyslaw Twardowski; D Asuncion; James Doroshow; Stephen Forman; Paul Frankel; Marianna Koczywas; Lucille Leong; T Luu; Kim Margolin; Robert Morgan; I B Paz; Richard D Pezner; Stephen Shibata; George Somlo
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(8):1273-80.
2012: William C Reinhold; Margot Sunshine; Sudhir Varma; James Doroshow; Kurt W Kohn; Hongfang Liu; Joel Morris; Yves Pommier
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.
Cancer research 2012;72(14):3499-511.
2012: Shivaani Kummar; Heinz-Josef Lenz; Robert Morgan; Edward M Newman; Ralph E Parchment; Shannon L Puhalla; Larry Rubinstein; Joseph E Tomaszewski; Lihua Wang; Yiping Zhang; Deborah Allen; Chandra P Belani; Jan H Beumer; Alice Chen; David R Gandara; Jiuping Ji; Brian Kiesel; Robert Kinders; James Doroshow
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1726-34.
2011: Mark J Ratain; J M Collins; James Doroshow
Merrill Jon Egorin, MD, 1948-2010.
Clinical pharmacology and therapeutics 2011;89(2):163-5.
2010: Robert Kinders; Melinda G Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James Doroshow
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5447-57.
2010: Robert J Morgan; Timothy W Synold; Adam N Mamelak; Dean Lim; Zaid Al-Kadhimi; Przemyslaw Twardowski; Lucille Leong; Warren Chow; Kim Margolin; Stephen Shibata; George Somlo; Yun Yen; Paul Frankel; James Doroshow
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Cancer chemotherapy and pharmacology 2010;66(5):927-33.
2010: Christophe E Redon; Asako J Nakamura; Yong-Wei Zhang; Jiuping Jay Ji; William M Bonner; Robert Kinders; Ralph E Parchment; James Doroshow; Yves Pommier
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(18):4532-42.
2010: William C Reinhold; Jean-Louis Mergny; Hongfang Liu; Michael Ryan; Thomas D Pfister; Robert Kinders; Ralph Parchment; James Doroshow; John N Weinstein; Yves Pommier
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.
Cancer research 2010;70(6):2191-203.
2010: Lihua H Wang; Thomas D Pfister; Ralph E Parchment; Shivaani Kummar; Larry Rubinstein; Yvonne A Evrard; Martin E Gutierrez; Anthony J Murgo; Joseph E Tomaszewski; James Doroshow; Robert Kinders
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(3):1073-84.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; Xiaohong Chen; William D Figg; Maria Zajac-Kaye; Min Chen; Seth M Steinberg; Christine A Muir; Mary Ann Yancey; Yvonne R Horneffer; Lamin Juwara; Giovanni Melillo; S Percy Ivy; Maria Merino; Len Neckers; Patricia S Steeg; BA Conley; Giuseppe Giaccone; James Doroshow; Anthony J Murgo
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2010;46(2):340-7.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; William D Figg; Giovanni Melillo; Janet Dancey; Edward A Sausville; BA Conley; Anthony J Murgo; James Doroshow
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Cancer chemotherapy and pharmacology 2010;65(2):383-9.
2009: Stephen I Shibata; James Doroshow; Paul Frankel; Timothy W Synold; Yun Yen; David R Gandara; Heinz-Josef Lenz; Warren A Chow; Lucille A Leong; Dean Lim; Kim Margolin; Robert J Morgan; George Somlo; Edward M Newman
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Cancer chemotherapy and pharmacology 2009;64(6):1149-55.
2009: Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert Kinders; Ralph E Parchment; Joseph E Tomaszewski; James Doroshow; Yves Pommier
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Molecular cancer therapeutics 2009;8(7):1878-84.
2009: Agnes Juhasz; Yun Ge; Susan Markel; Alice Chiu; Linda Matsumoto; Josephus van Balgooy; Krishnendu Roy; James Doroshow
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues.
Free radical research 2009;43(6):523-32.
2009: Shivaani Kummar; Robert Kinders; Martin E Gutierrez; Larry Rubinstein; Ralph E Parchment; Lawrence R Phillips; Jiuping Ji; Anne Monks; Jennifer A Low; Alice Chen; Anthony J Murgo; Jerry Collins; Seth M Steinberg; Helen Eliopoulos; Vincent L Giranda; Gary Gordon; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2705-11.
2009: Helen K Chew; James Doroshow; Paul Frankel; Kim Margolin; George Somlo; Heinz-Josef Lenz; Michael Gordon; Wu Zhang; Dongyun Yang; Christy Russell; Darcy Spicer; Timothy W Synold; Robert Bayer; Alexander Hantel; Patrick J Stiff; Merry L Tetef; David R Gandara; Kathy S Albain
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2163-9.
2009: Shivaani Kummar; James Doroshow; Joseph E Tomaszewski; A Hilary Calvert; Marinus Lobbezoo; Giuseppe Giaccone
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.
European journal of cancer (Oxford, England : 1990) 2009;45(5):741-6.
2009: James Doroshow; Robert T Croyle; John E Niederhuber
Five strategies for accelerating the war on cancer in an era of budget deficits.
The oncologist 2009;14(2):110-6.
2008: Thehang H Luu; Robert J Morgan; Lucille Leong; Dean Lim; Mark McNamara; Jana Portnow; Paul Frankel; David D Smith; James Doroshow; Carol Wong; Ana Aparicio; David R Gandara; George Somlo
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7138-42.
2008: Robert Kinders; Melinda G Hollingshead; Sonny Khin; Larry Rubinstein; Joseph E Tomaszewski; James Doroshow; Ralph E Parchment
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6877-85.
2008: G Somlo; P Chu; P Frankel; W Ye; S Groshen; James Doroshow; K Danenberg; P Danenberg
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(11):1853-9.
2008: James Doroshow
Commentary: publishing cancer clinical trial results: a scientific and ethical imperative.
The oncologist 2008;13(9):930-2.
2008: Jan H Beumer; Robert A Parise; Edward M Newman; James Doroshow; Timothy W Synold; Heinz-Josef Lenz; Merrill J Egorin
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Cancer chemotherapy and pharmacology 2008;62(2):363-8.
2008: Anthony J Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E Parchment; Jiuping Ji; Seth M Steinberg; Sherry X Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Designing phase 0 cancer clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3675-82.
2008: James Doroshow; Ralph E Parchment
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3658-63.
2008: Shivaani Kummar; Larry Rubinstein; Robert Kinders; Ralph E Parchment; Martin E Gutierrez; Anthony J Murgo; Jay Ji; Barbara Mroczkowski; Oxana Pickeral; Mel Simpson; Melinda G Hollingshead; Sherry X Yang; Lee Helman; Robert Wiltrout; Jerry Collins; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials: conceptions and misconceptions.
Cancer journal (Sudbury, Mass.) 2008;14(3):133-7.
2008: Ramesh K Ramanathan; Merrill J Egorin; Chris H Takimoto; Scot C Remick; James Doroshow; Patricia M LoRusso; Daniel Mulkerin; Jean L Grem; Anne Hamilton; Anthony J Murgo; Douglas M Potter; Chandra P Belani; Michael J Hayes; Bin Peng; S Percy Ivy
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):563-9.
2007: Robert Kinders; Ralph E Parchment; Jay Ji; Shivaani Kummar; Anthony J Murgo; Martin Gutierrez; Jerry Collins; Larry Rubinstein; Oxana Pickeral; Seth M Steinberg; Sherry Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Mel Simpson; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Molecular interventions 2007;7(6):325-34.
2007: Shivaani Kummar; Martin Gutierrez; Erin R Gardner; Erin Donovan; Kyunghwa Hwang; Eun Joo Chung; Min-Jung Lee; Kim Maynard; Mikhail Kalnitskiy; Alice Chen; Giovanni Melillo; Qin C Ryan; BA Conley; William D Figg; Jane Trepel; James Zwiebel; James Doroshow; Anthony J Murgo
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5411-7.
2007: Chris H Takimoto; Martin A Graham; Graham Lockwood; Chee M Ng; Andrew Goetz; Dennis Greenslade; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; Timothy W Synold; James Doroshow; Anne Hamilton; Daniel Mulkerin; Percy Ivy; Merrill J Egorin; Jean L Grem
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4832-9.
2007: Timothy W Synold; Chris H Takimoto; James Doroshow; David R Gandara; Sridhar Mani; Scot C Remick; Daniel Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz-Josef Lenz; Martin Graham; Jeff Longmate; Bennett M Kaufman; Percy Ivy
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3660-6.
2007: Ewa Gajewski; Shikha Gaur; Steven A Akman; Linda Matsumoto; Josephus N A van Balgooy; James Doroshow
Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin.
Biochemical pharmacology 2007;73(12):1947-56.
2007: Robert J Morgan; Timothy W Synold; David R Gandara; Franco Muggia; Sidney Scudder; E Reed; Kim Margolin; James Raschko; Lucille Leong; Stephen Shibata; Merry Tetef; Steven Vasilev; Kathryn F McGonigle; Jeff Longmate; Yun Yen; Warren Chow; George Somlo; Mary Carroll; James Doroshow
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(2):373-8.
2007: Stephen Shibata; Warren Chow; Paul Frankel; Agnes Juhasz; Lucille Leong; Dean Lim; Kim Margolin; Robert Morgan; Edward Newman; George Somlo; Yun Yen; Timothy W Synold; David R Gandara; Heinz-Josef Lenz; James Doroshow
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Cancer chemotherapy and pharmacology 2007;59(4):549-57.
2007: Robert J Morgan; Timothy W Synold; Bixin Xi; Dean Lim; Stephen Shibata; Kim Margolin; Roderich E Schwarz; Lucille Leong; George Somlo; Przemyslaw Twardowski; Yun Yen; Warren Chow; Merry Tetef; Paul Lin; Benjamin Paz; Mariana Koczywas; Lawrence D Wagman; David Chu; Paul Frankel; Susan Stalter; James Doroshow
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1232-7.
2007: Shivaani Kummar; Robert Kinders; Larry Rubinstein; Ralph E Parchment; Anthony J Murgo; Jerry Collins; Oxana Pickeral; Jennifer Low; Seth M Steinberg; Martin Gutierrez; Sherry Yang; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Compressing drug development timelines in oncology using phase '0' trials.
Nature reviews. Cancer 2007;7(2):131-9.
2006: Indranil Mukhopadhyay; Edward A Sausville; James Doroshow; Krishnendu K Roy
Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways.
The Journal of biological chemistry 2006;281(49):37330-44.
2006: Antoinette R Tan; Dirk Moore; Manuel Hidalgo; James Doroshow; Elizabeth Poplin; Susan Goodin; David J Mauro; Eric H Rubin
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6517-22.
2006: James Doroshow; Sheryl McCoy; John S Macdonald; Brian F Issell; Taral Patel; Patrick W Cobb; Kathleen J Yost; James L Abbruzzese
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
Investigational new drugs 2006;24(6):537-42.
2006: Paul J Hesketh; Kari Chansky; Derick H Lau; James Doroshow; Carol M Moinpour; Robert A Chapman; J Wendall Goodwin; Howard M Gross; John J Crowley; David R Gandara
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(6):537-44.
2006: Shivaani Kummar; Martin Gutierrez; James Doroshow; Anthony J Murgo
Drug development in oncology: classical cytotoxics and molecularly targeted agents.
British journal of clinical pharmacology 2006;62(1):15-26.
2006: Primo Lara; Walter M Stadler; Jeff Longmate; David I Quinn; Jason Wexler; Marta D Van Loan; Przemyslaw Twardowski; Paul H Gumerlock; Nicholas J Vogelzang; Everett E Vokes; Heinz-Josef Lenz; James Doroshow; David R Gandara
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1556-63.
2006: James Doroshow
Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity.
Journal of the National Cancer Institute 2006;98(4):223-5.
2006: Primo Lara; Mariana Koczywas; David I Quinn; Heinz-Josef Lenz; Angela M Davies; Derick H Lau; Paul H Gumerlock; Jeff Longmate; James Doroshow; David P Schenkein; Oscar Kashala; David R Gandara
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(2):126-34.
2006: Milin R Acharya; Alex Sparreboom; Edward A Sausville; BA Conley; James Doroshow; Jürgen Venitz; William D Figg
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
2005: Kim Margolin; James Doroshow; Paul Frankel; Warren Chow; Lucille A Leong; Dean Lim; Mark McNamara; Robert J Morgan; Stephen Shibata; George Somlo; Przemyslaw Twardowski; Yun Yen; Neil Kogut; Jeffrey Schriber; Joseph Alvarnas; Susan Stalter
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2005;11(11):903-11.
2005: Kim Margolin; Jeff Longmate; Tracey Baratta; Timothy W Synold; Scott Christensen; Jeffrey Weber; Thomas Gajewski; Ian Quirt; James Doroshow
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
Cancer 2005;104(5):1045-8.
2005: James Doroshow
Targeting EGFR in non-small-cell lung cancer.
The New England journal of medicine 2005;353(2):200-2.
2005: Primo Lara; Philip C Mack; Timothy W Synold; Paul Frankel; Jeff Longmate; Paul H Gumerlock; James Doroshow; David R Gandara
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4444-50.
2005: Dean Lim; Robert J Morgan; Steven Akman; Kim Margolin; Brian I Carr; Lucille Leong; Oluwole Odujinrin; James Doroshow
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.
Investigational new drugs 2005;23(3):235-9.
2005: James Doroshow
The role of the National Cancer Institute in drug development.
Clinical advances in hematology & oncology : H&O 2005;3(4):257-8.
2005: Primo Lara; Lisa Y Law; John J Wright; Paul Frankel; Przemyslaw Twardowski; Heinz-Josef Lenz; Derick H Lau; Tomoya Kawaguchi; Paul H Gumerlock; James Doroshow; David R Gandara
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anti-cancer drugs 2005;16(3):317-21.
2004: Robert J Morgan; Timothy W Synold; David R Gandara; Franco Muggia; Sidney Scudder; Eddie Reed; Kim Margolin; James Raschko; Lucille Leong; Stephen Shibata; Merry Tetef; Steven Vasilev; Kathryn F McGonigle; Jeff Longmate; Yun Yen; Warren Chow; George Somlo; Mary Carroll; James Doroshow
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Cancer chemotherapy and pharmacology 2004;54(4):283-9.
2004: Yun Yen; Kim Margolin; James Doroshow; Mayer Fishman; Bonny Johnson; Caroline Clairmont; Dan Sullivan; Mario Sznol
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Cancer chemotherapy and pharmacology 2004;54(4):331-42.
2004: Primo Lara; Paul H Gumerlock; Philip C Mack; Derick H Lau; Regina Gandour-Edwards; Martin J Edelman; Kathy S Albain; Lisa Y Law; Jeff Longmate; Paul Frankel; Gayatri P Reddy; Valerie Israel; James Doroshow; David R Gandara
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clinical lung cancer 2004;6(2):102-7.
2004: Warren A Chow; Timothy W Synold; Merry Tetef; Jeff Longmate; Paul Frankel; Joyce Lawrence; Zaid Al-Khadimi; Lucille Leong; Dean Lim; Kim Margolin; Robert J Morgan; James Raschko; Stephen Shibata; George Somlo; Przemyslaw Twardowski; Yun Yen; James Doroshow
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Cancer chemotherapy and pharmacology 2004;54(3):241-8.
2004: Stephen Shibata; Richard D Pezner; David Chu; James Doroshow; Warren A Chow; Lucille A Leong; Kim Margolin; Mark McNamara; Robert J Morgan; James Raschko; George Somlo; Merry Tetef; Yun Yen; Timothy W Synold; Lawrence D Wagman; Nayana L Vora; Mary Carroll; S Lin; Jeff Longmate
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2004;30(6):650-7.
2004: Fong-Fong Chu; R Steven Esworthy; James Doroshow
Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer.
Free radical biology & medicine 2004;36(12):1481-95.
2004: Tatsuo Kimura; Will S Holland; Tomoya Kawaguchi; Stephen K Williamson; Kari Chansky; John J Crowley; James Doroshow; Heinz-Josef Lenz; David R Gandara; Paul H Gumerlock
Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
Annals of the New York Academy of Sciences 2004;1022():55-60.
2004: George Somlo; Paul Frankel; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; Stephen Shibata; Peiguo Chu; Stephen Forman; Dean Lim; Przemyslaw Twardowski; Jeffrey N Weitzel; Joseph Alvarnas; Neil Kogut; Jeffrey Schriber; Eleanor Fermin; Yun Yen; Lloyd Damon; James Doroshow
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(10):1839-48.
2004: Primo Lara; Karen Giselle Chee; Jeff Longmate; Christopher Ruel; Frederick J Meyers; Carl R Gray; Regina Gandour-Edwards; Paul H Gumerlock; Przemyslaw Twardowski; James Doroshow; David R Gandara
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Cancer 2004;100(10):2125-31.
2004: Glenn Liu; David R Gandara; Primo Lara; Derek Raghavan; James Doroshow; Przemyslaw Twardowski; Philip W Kantoff; William K Oh; KyungMann Kim; George Wilding
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):924-8.
2004: Fong-Fong Chu; R Steven Esworthy; Peiguo G Chu; Jeff Longmate; Mark M Huycke; Sharon P Wilczynski; James Doroshow
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes.
Cancer research 2004;64(3):962-8.
2004: Harry Openshaw; Karen Beamon; Timothy W Synold; Jeff Longmate; Neal E Slatkin; James Doroshow; Stephen Forman; Kim Margolin; Robert Morgan; Stephen Shibata; George Somlo
Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(2):461-7.
2004: Primo Lara; Luko Laptalo; Jeff Longmate; Derick H Lau; Regina Gandour-Edwards; Paul H Gumerlock; James Doroshow; David R Gandara
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clinical lung cancer 2004;5(4):231-6.
2003: Robert J Morgan; James Doroshow; Timothy W Synold; Dean Lim; Stephen Shibata; Kim Margolin; Roderich Schwarz; Lucille Leong; George Somlo; Przemyslaw Twardowski; Yun Yen; Warren Chow; Paul Lin; Benjamin Paz; David Chu; Paul Frankel; Susan Stalter
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5896-901.
2003: Jeffrey Y C Wong; Stephen Shibata; Lawrence E Williams; Cheuk S Kwok; An Liu; David Z J Chu; Dave M Yamauchi; Sharon P Wilczynski; David Ikle; Anna M Wu; Paul J Yazaki; John E Shively; James Doroshow; Andrew Raubitschek
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5842-52.
2003: Primo Lara; David I Quinn; Kim Margolin; Frederick J Meyers; Jeff Longmate; Paul Frankel; Philip C Mack; Corinne Turrell; Peter Valk; Jyotsna Rao; Penelope Buckley; Ted Wun; Robert C Gosselin; Irina Galvin; Paul H Gumerlock; Heinz-Josef Lenz; James Doroshow; David R Gandara
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4772-81.
2003: Primo Lara; Paul Frankel; Philip C Mack; Paul H Gumerlock; Irina Galvin; Cynthia L Martel; Jeff Longmate; James Doroshow; Heinz-Josef Lenz; Derick H Lau; David R Gandara
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4356-62.
2003: Albert J ten Tije; Timothy W Synold; Darcy Spicer; Jaap Verweij; James Doroshow; Alex Sparreboom
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Investigational new drugs 2003;21(3):291-8.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Dennis Greenslade; Andrew Goetz; Jean L Grem
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
Seminars in oncology 2003;30(4 Suppl 15):20-5.
2003: James Doroshow; Timothy W Synold; David R Gandara; Sridhar Mani; Scot C Remick; Daniel Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz-Josef Lenz; Martin Graham; Jeff Longmate; Chris H Takimoto; Percy Ivy
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Seminars in oncology 2003;30(4 Suppl 15):14-9.
2003: Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill J Egorin; Barbara Schuler; Dennis Greenslade; Andrew Goetz; Ronald Knight; Rebecca Thomas; Brian P Monahan; William Dahut; Jean L Grem
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2664-72.
2003: Robert J Morgan; Edward M Newman; Lawrence C Sowers; Kevin Scanlon; Jonathan Harrison; Steven Akman; Lucille Leong; Kim Margolin; Joyce C Niland; James Raschko; George Somlo; Mary Carroll; Warren Chow; Merry Tetef; Victor Hamasaki; Yun Yen; James Doroshow
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2003;51(6):459-64.
2003: R Steven Esworthy; Scott W Binder; James Doroshow; Fong-Fong Chu
Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression.
Biological chemistry 2003;384(4):597-607.
2003: Agnes Juhasz; Paul Frankel; Catherine Cheng; Hector Rivera; Reena Vishwanath; Alice Chiu; Kim Margolin; Yun Yen; Edward M Newman; Timothy W Synold; Sharon P Wilczynski; Heinz-Josef Lenz; David R Gandara; Kathy S Albain; Jeff Longmate; James Doroshow
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Journal of clinical laboratory analysis 2003;17(5):184-94.
2002: Yun Yen; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; James Raschko; Stephen Shibata; George Somlo; Przemyslaw Twardowski; Paul Frankel; Jeff Longmate; Timothy W Synold; Edward M Newman; Heinz-Josef Lenz; David R Gandara; James Doroshow
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2002;50(5):353-9.
2002: George Somlo; J F Simpson; Paul Frankel; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; James Raschko; Stephen Shibata; Stephen Forman; Neil Kogut; Mark McNamara; Arturo Molina; E Somlo; James Doroshow
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer.
British journal of cancer 2002;87(3):281-8.
2002: Primo Lara; Frederick J Meyers; Carl R Gray; Regina Gandour-Edwards; Paul H Gumerlock; Caren Kauderer; Garrett Tichauer; Przemyslaw Twardowski; James Doroshow; David R Gandara
HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
Cancer 2002;94(10):2584-9.
2001: Alan F List; Kenneth J Kopecky; Cheryl L Willman; David R Head; Diane L Persons; Marilyn L Slovak; R Dorr; Chatchada Karanes; HE Hynes; James Doroshow; M Shurafa; Frederick R Appelbaum
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
Blood 2001;98(12):3212-20.
2001: Robert J Morgan; James Doroshow; Lucille Leong; Jeffrey Schriber; Stephen Shibata; Stephen Forman; Victor Hamasaki; Kim Margolin; George Somlo; Joseph Alvarnas; Mark McNamara; Jeff Longmate; James Raschko; Warren Chow; Steven Vasilev; Kathryn F McGonigle; Yun Yen
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer.
Bone marrow transplantation 2001;28(9):859-63.
2001: Susan E Kane; L Matsumoto; Marianne Z Metz; Cécile A Donohue; R G Lingeman; S W Lin; James Doroshow
MDR1 bicistronic vectors: analysis of selection stringency, amplified gene expression, and vector stability in cell lines.
Biochemical pharmacology 2001;62(6):693-704.
2001: R Steven Esworthy; Richard Aranda; Martín G Martín; James Doroshow; Scott W Binder; Fong-Fong Chu
Mice with combined disruption of Gpx1 and Gpx2 genes have colitis.
American journal of physiology. Gastrointestinal and liver physiology 2001;281(3):G848-55.
2001: Primo Lara; David R Gandara; Jeff Longmate; Paul H Gumerlock; Derick H Lau; Martin J Edelman; Regina Gandour-Edwards; Philip C Mack; Valerie Israel; James Raschko; Paul Frankel; E A Perez; Heinz-Josef Lenz; James Doroshow
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2001;48(1):22-8.
2001: George Somlo; James Doroshow; Timothy W Synold; Jeff Longmate; D Reardon; Warren Chow; Stephen J Forman; Lucille A Leong; Kim Margolin; Robert J Morgan; James Raschko; Stephen Shibata; Merry Tetef; Yun Yen; Neil Kogut; Jeffrey Schriber; Joseph Alvarnas
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
British journal of cancer 2001;84(12):1591-8.
2001: Merry Tetef; Timothy W Synold; Warren Chow; Lucille Leong; Kim Margolin; Robert Morgan; James Raschko; Stephen Shibata; George Somlo; Yun Yen; S Groshen; K Johnson; Heinz-Josef Lenz; David R Gandara; James Doroshow
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1569-76.
2001: James Doroshow; Timothy W Synold; George Somlo; S A Akman; E Gajewski
Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin.
Blood 2001;97(9):2839-45.
2001: Robert J Morgan; Timothy W Synold; B I Carr; James Doroshow; E P Womack; Stephen Shibata; George Somlo; James Raschko; Lucille Leong; Mark McNamara; Warren Chow; Merry Tetef; Kim Margolin; Steven Akman; Jeff Longmate
Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy.
Cancer chemotherapy and pharmacology 2001;47(4):327-32.
2001: Derick H Lau; Bryan R Leigh; David R Gandara; Martin J Edelman; R Morgan; V Israel; Primo Lara; R Wilder; J Ryu; James Doroshow
Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):442-7.
2001: Kim Margolin; Timothy W Synold; Jeff Longmate; James Doroshow
Methodologic guidelines for the design of high-dose chemotherapy regimens.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(8):414-32.
2001: Kim Margolin; Jeff Longmate; Timothy W Synold; David R Gandara; Jeffrey Weber; R Gonzalez; M J Johansen; R Newman; Tracey Baratta; James Doroshow
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.
Investigational new drugs 2001;19(4):335-40.
2000: Al B Benson; Michael A Choti; A M Cohen; James Doroshow; C Fuchs; Krystyna Kiel; Edward W Martin; C McGinn; N J Petrelli; James A Posey; John M Skibber; Alan P Venook; T J Yeatman
NCCN Practice Guidelines for Colorectal Cancer.
Oncology (Williston Park, N.Y.) 2000;14(11A):203-12.
2000: David Z J Chu; Dave M Yamauchi; Lawrence E Williams; An Liu; Sharon P Wilczynski; Anna M Wu; John E Shively; James Doroshow; Andrew Raubitschek
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3855-63.
2000: Robert J Morgan; P Braly; Lucille Leong; Stephen Shibata; Kim Margolin; George Somlo; Mark McNamara; Jeff Longmate; S Schinke; James Raschko; S Nagasawa; Neil Kogut; L Najera; D Johnson; James Doroshow
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Gynecologic oncology 2000;77(3):433-8.
2000: James Raschko; Timothy W Synold; Warren Chow; PH Coluzzi; Victor Hamasaki; Lucille A Leong; Kim Margolin; Robert J Morgan; Stephen Shibata; George Somlo; Merry Tetef; Yun Yen; A ter Veer; James Doroshow
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Cancer chemotherapy and pharmacology 2000;46(5):403-10.
2000: Merry Tetef; Kim Margolin; James Doroshow; Steven Akman; Lucille A Leong; Robert J Morgan; James Raschko; Neal E Slatkin; George Somlo; Jeff Longmate; M I Carroll; Edward M Newman
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Cancer chemotherapy and pharmacology 2000;46(1):19-26.
1999: Robert J Morgan; P Braly; G Cecchi; Lucille Leong; Stephen Shibata; Kim Margolin; George Somlo; Mark McNamara; Jeff Longmate; S Schinke; James Raschko; S Nagasawa; Neil Kogut; Pablo Parker; Anthony Stein; J Cho; E Smith; PH Coluzzi; L Najera; D Johnson; E Womack; James Doroshow
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Gynecologic oncology 1999;75(3):419-26.
1999: H J Lenz; D Raghavan; James Doroshow; David R Gandara
Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer.
Clinical lung cancer 1999;1(2):151-2.
1999: Jeffrey Y C Wong; George Somlo; TL Odom-Maryon; Lawrence E Williams; An Liu; Dave M Yamauchi; Anna M Wu; Paul J Yazaki; Sharon P Wilczynski; John E Shively; Stephen Forman; James Doroshow; Andrew Raubitschek
Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3224s-3231s.
1999: Cynthia G Leichman; J R Jacobson; M Modiano; J R Daniels; Mark M Zalupski; James Doroshow; W S Fletcher; John S Macdonald
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
Cancer 1999;86(5):775-81.
1999: George Somlo; Irena Sniecinski; A ter Veer; Jeff Longmate; Gaylord J Knutson; S Vuk-Pavlovic; Ravi Bhatia; Warren Chow; Lucille Leong; Robert Morgan; Kim Margolin; James Raschko; Stephen Shibata; Merry Tetef; Yun Yen; Stephen Forman; Denny Jones; Mark Ashby; Gwen Fyfe; Sue Hellmann; James Doroshow
Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Blood 1999;93(9):2798-806.
1999: Derick H Lau; J Ryu; David R Gandara; R Morgan; James Doroshow; R Wilder; Bryan R Leigh
Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):117-20.
1999: Merry Tetef; Lucille Leong; Chul Ahn; Steven Akman; Warren Chow; Kim Margolin; Robert J Morgan; James Raschko; Stephen Shibata; George Somlo; James Doroshow
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trial.
Cancer investigation 1999;17(2):114-7.
1998: Timothy W Synold; Edward M Newman; Mary Carroll; F M Muggia; S Groshen; K Johnson; James Doroshow
Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2349-55.
1998: Priscilla Yam; Jiing-Kuan Yee; J I Ito; Irena Sniecinski; James Doroshow; Stephen J Forman; John A Zaia
Comparison of amphotropic and pseudotyped VSV-G retroviral transduction in human CD34+ peripheral blood progenitor cells from adult donors with HIV-1 infection or cancer.
Experimental hematology 1998;26(10):962-8.
1998: Timothy W Synold; Merry Tetef; James Doroshow
Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
Seminars in oncology 1998;25(4 Suppl 10):93-9.
1998: Robert J Morgan; Edward M Newman; James Doroshow; Kathryn F McGonigle; Kim Margolin; James Raschko; Warren Chow; George Somlo; Lucille Leong; Merry Tetef; Stephen Shibata; Victor Hamasaki; Mary Carroll; Steven Vasilev; Steven Akman; PH Coluzzi; Lawrence D Wagman; Jeff Longmate; Benjamin Paz; Yun Yen; Robert R Klevecz
Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Cancer research 1998;58(13):2793-800.
1998: Martin J Edelman; Frederick J Meyers; T Grennan; J Lauder; James Doroshow
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer.
Investigational new drugs 1998;16(2):179-82.
1998: Primo Lara; David R Gandara; G T Wurz; Derick H Lau; M Uhrich; Corinne Turrell; James Raschko; Martin J Edelman; Timothy W Synold; James Doroshow; Franco Muggia; E A Perez; Michael W DeGregorio
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.
Cancer chemotherapy and pharmacology 1998;42(6):504-8.
1997: Robert J Morgan; James Doroshow; K Venkataraman; K Chang; James Raschko; George Somlo; Lucille Leong; Merry Tetef; Stephen Shibata; Victor Hamasaki; Kim Margolin; Stephen Forman; Steven Akman; PH Coluzzi; Chul Ahn; L Weiss; U Gadgil; J Harrison
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2337-45.
1997: Derick H Lau; J K Ryu; David R Gandara; R Morgan; James Doroshow; R Wilder; Bryan R Leigh
Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-106-S12-109.
1997: George Somlo; James Doroshow; Stephen J Forman; TL Odom-Maryon; J Lee; Warren Chow; Victor Hamasaki; Lucille Leong; Robert Morgan; Kim Margolin; James Raschko; Stephen Shibata; Merry Tetef; Yun Yen; J Simpson; Arturo Molina
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(8):2882-93.
1997: Janice P Dutcher; Richard I Fisher; G Weiss; Frederick R Aronson; K Margolin; A Louie; James W Mier; G Caliendo; Jeffrey A Sosman; J R Eckardt; M L Ernest; James Doroshow; M Atkins
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
The cancer journal from Scientific American 1997;3(3):157-62.
1997: Kim Margolin; Michael Atkins; Joseph A Sparano; Jeffrey A Sosman; G Weiss; Michael Lotze; James Doroshow; James W Mier; K O'Boyle; Richard I Fisher; E Campbell; Joshua Rubin; D Federighi; SL Bursten
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):565-72.
1997: George Somlo; Irena Sniecinski; TL Odom-Maryon; B Nowicki; Warren Chow; Victor Hamasaki; Lucille Leong; Kim Margolin; Robert Morgan; James Raschko; Stephen Shibata; Merry Tetef; Arturo Molina; R J Berenson; Stephen J Forman; James Doroshow
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
Blood 1997;89(5):1521-8.
1997: Jeffrey A Sosman; Frederick R Aronson; Mario Sznol; Michael B Atkins; Janice P Dutcher; Geoffrey R Weiss; R E Isaacs; Kim Margolin; Richard I Fisher; M L Ernest; James W Mier; L Oleksowicz; J R Eckhardt; D Levitt; James Doroshow
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):39-46.
1997: Edward M Newman; Mary Carroll; Steven Akman; Warren Chow; PH Coluzzi; Victor Hamasaki; Lucille A Leong; Kim Margolin; Robert J Morgan; James Raschko; Stephen Shibata; George Somlo; Merry Tetef; Yun Yen; Chul Ahn; James Doroshow
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 1997;39(3):254-8.
1996: P F Engstrom; A B Benson; A Cohen; James Doroshow; K Kiel; John E Niederhuber; M Roh; M Tempero
NCCN Colorectal Cancer Practice Guidelines. The National Comprehensive Cancer Network.
Oncology (Williston Park, N.Y.) 1996;10(11 Suppl):140-75.
1996: F M Muggia; Timothy W Synold; Edward M Newman; Susan Jeffers; L P Leichman; James Doroshow; K Johnson; Susan Groshen
Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol.
Journal of the National Cancer Institute 1996;88(20):1495-6.
1996: Kim Margolin; James Doroshow; Chul Ahn; Victor Hamasaki; Lucille Leong; Robert Morgan; James Raschko; Stephen Shibata; George Somlo; Merry Tetef
Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2631-7.
1996: Timothy W Synold; B Xi; Edward M Newman; F M Muggia; James Doroshow
Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Biomedical applications 1996;683(2):245-9.
1996: James Doroshow
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?
Journal of the National Cancer Institute 1996;88(7):393-5.
1996: M Z Metz; L Matsumoto; K A Winters; James Doroshow; Susan E Kane
Bicistronic and two-gene retroviral vectors for using MDR1 as a selectable marker and a therapeutic gene.
Virology 1996;217(1):230-41.
1996: Timothy W Synold; James Doroshow
Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
The Journal of infusional chemotherapy 1996;6(2):69-73.
1995: James Doroshow
Glutathione peroxidase and oxidative stress.
Toxicology letters 1995;82-83():395-8.
1995: Frank L Meyskens; K J Kopecky; C W Taylor; R D Noyes; R J Tuthill; Evan M Hersh; Lynn Feun; James Doroshow; Lawrence E Flaherty; vernon sondak
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1995;87(22):1710-3.
1995: B Gonzalez; Steven Akman; James Doroshow; H Rivera; W D Kaplan; G L Forrest
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.
Cancer research 1995;55(20):4646-50.
1995: James Doroshow; M Z Metz; L Matsumoto; K A Winters; M Sakai; M Muramatsu; Susan E Kane
Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad-range multidrug resistance.
Cancer research 1995;55(18):4073-8.
1995: Robert J Morgan; Kim Margolin; James Raschko; Steven Akman; Lucille Leong; George Somlo; K Scanlon; Chul Ahn; M Carroll; James Doroshow
Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2238-46.
1995: Henry Rodriguez; Régen Drouin; Gerald P Holmquist; Timothy R O'Connor; Serge Boiteux; Jacques Laval; James Doroshow; Steven Akman
Mapping of copper/hydrogen peroxide-induced DNA damage at nucleotide resolution in human genomic DNA by ligation-mediated polymerase chain reaction.
The Journal of biological chemistry 1995;270(29):17633-40.
1995: G R Weiss; Kim Margolin; Mario Sznol; Michael B Atkins; L Oleksowicz; R Isaacs; Jeffrey A Sosman; James Doroshow; E G Trehu; Janice P Dutcher
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(1):52-6.
1995: Robert J Morgan; James Speyer; James Doroshow; Kim Margolin; James Raschko; Joan Sorich; Steven Akman; Lucille Leong; George Somlo; Steven Vasilev
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
Gynecologic oncology 1995;58(1):79-85.
1995: Jeanna Welborn; Kenneth J Kopecky; Frederick J Meyers; R Veith; M Shurafa; James Doroshow; Stanley P Balcerzak; F R Appelbaum
Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial.
Leukemia 1995;9(7):1126-9.
1995: Cynthia G Leichman; T R Fleming; F M Muggia; C M Tangen; Bach Ardalan; James Doroshow; Frederick J Meyers; R F Holcombe; G R Weiss; A Mangalik
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1303-11.
1995: George Somlo; James Doroshow; A Lev-Ran; D C Ahn; L Hwang; James Raschko; Stephen J Forman; Kim Margolin; Robert J Morgan; L A Leong
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1231-7.
1995: Bing-Sen Zhou; N Y Hsu; B C Pan; James Doroshow; Yun Yen
Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.
Cancer research 1995;55(6):1328-33.
1995: PH Coluzzi; Marcia Grant; James Doroshow; M Rhiner; Betty Ferrell; L Rivera
Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):756-64.
1995: Merry Tetef; Kim Margolin; Chul Ahn; Steven Akman; Warren Chow; Lucille Leong; Robert J Morgan; James Raschko; George Somlo; James Doroshow
Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.
Investigational new drugs 1995;13(2):157-62.
1995: K Erkmen; Merrill J Egorin; L M Reyno; R Morgan; James Doroshow
Effects of storage on the binding of carboplatin to plasma proteins.
Cancer chemotherapy and pharmacology 1995;35(3):254-6.
1995: Kim Margolin; Steven Akman; L A Leong; Robert J Morgan; George Somlo; James Raschko; Chul Ahn; James Doroshow
Phase I study of mitomycin C and menadione in advanced solid tumors.
Cancer chemotherapy and pharmacology 1995;36(4):293-8.
1995: Merry Tetef; James Doroshow; Steven Akman; PH Coluzzi; Lucille Leong; Kim Margolin; Robert J Morgan; James Raschko; Stephen Shibata; George Somlo
5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.
Cancer investigation 1995;13(5):460-3.
1994: R Steven Esworthy; K Doan; James Doroshow; Fong-Fong Chu
Cloning and sequencing of the cDNA encoding a human testis phospholipid hydroperoxide glutathione peroxidase.
Gene 1994;144(2):317-8.
1994: Kim Margolin; S Green; C Kent Osborne; James Doroshow; Steven Akman; L A Leong; Robert J Morgan; James Raschko; George Somlo; L Hutchins
Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer.
American journal of clinical oncology 1994;17(2):175-80.
1994: George Somlo; James Doroshow; Stephen J Forman; L A Leong; Kim Margolin; Robert J Morgan; James Raschko; Steven Akman; Chul Ahn; S Nagasawa
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Cancer 1994;73(6):1678-85.
1994: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; Rasim Gucalp; Richard I Fisher; M Sunderland; James Doroshow; M L Ernest; James W Mier
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):147-53.
1994: James Raschko; Steven Akman; L A Leong; Kim Margolin; Robert J Morgan; E Newman; George Somlo; Chul Ahn; James Doroshow
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Cancer chemotherapy and pharmacology 1994;35(2):161-4.
1994: George Somlo; James Doroshow; Stephen J Forman; L A Leong; Kim Margolin; Robert J Morgan; James Raschko; Steven Akman; Chul Ahn; Irena Sniecinski
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Cancer 1994;73(1):125-34.
1994: Peter M Ravdin; S Green; James Doroshow; S Martino
Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1994;12(4):333-6.
1993: R Steven Esworthy; Fong-Fong Chu; P Geiger; A W Girotti; James Doroshow
Reactivity of plasma glutathione peroxidase with hydroperoxide substrates and glutathione.
Archives of biochemistry and biophysics 1993;307(1):29-34.
1993: Steven Akman; Thomas W Kensler; James Doroshow; M Dizdaroglu
Copper ion-mediated modification of bases in DNA in vitro by benzoyl peroxide.
Carcinogenesis 1993;14(9):1971-4.
1993: Jeffrey A Sosman; G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; K O'Boyle; Richard I Fisher; D H Boldt; James Doroshow
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1496-505.
1993: Kim Margolin; James Doroshow; Steven Akman; L A Leong; R Morgan; James Raschko; George Somlo; J Dutcher; K Hawksworth; L Yonemoto
Phase I trial of interleukin-2 plus doxorubicin.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(1):70-6.
1993: Douglas W Blayney; D A Goldberg; L A Leong; Kim Margolin; J S Burke; James Doroshow
High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
Cancer 1993;71(7):2351-7.
1993: Miral Dizdaroglu; Ryszard Olinski; James Doroshow; S A Akman
Modification of DNA bases in chromatin of intact target human cells by activated human polymorphonuclear leukocytes.
Cancer research 1993;53(6):1269-72.
1993: Fong-Fong Chu; James Doroshow; R Steven Esworthy
Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI.
The Journal of biological chemistry 1993;268(4):2571-6.
1993: James Doroshow; Kim Margolin; Lucille Leong; Steven Akman; Robert Morgan; James Raschko; George Somlo; Victor Hamasaki; E Womack; E Newman
Fluorouracil and leucovorin in advanced breast cancer.
Advances in experimental medicine and biology 1993;339():187-93; discussion 195.
1992: Eric H Kraut; J Bendetti; S P Balcerzak; James Doroshow
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
Investigational new drugs 1992;10(4):347-9.
1992: N T Sklarin; Peter H Wiernik; W R Grove; L Benson; A Mittelman; J A Maroun; James A Stewart; F Robert; James Doroshow; P J Rosen
A phase II trial of CI-921 in advanced malignancies.
Investigational new drugs 1992;10(4):309-12.
1992: Steven Akman; James Doroshow; Thomas W Kensler
Copper-dependent site-specific mutagenesis by benzoyl peroxide in the supF gene of the mutation reporter plasmid pS189.
Carcinogenesis 1992;13(10):1783-7.
1992: Kim Margolin; James Doroshow; Steven Akman; L A Leong; Robert J Morgan; George Somlo; James Raschko; C Pereira; L Yonemoto; C Ahn
Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1574-8.
1992: James Doroshow
Reductive activation of mitomycin C: a delicate balance.
Journal of the National Cancer Institute 1992;84(15):1138-9.
1992: Kim Margolin; James Doroshow; Steven Akman; L A Leong; Robert J Morgan; James Raschko; George Somlo; C Blevins
Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1278-83.
1992: Fong-Fong Chu; R Steven Esworthy; James Doroshow; K Doan; X F Liu
Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents.
Blood 1992;79(12):3233-8.
1992: Edward M Newman; Steven Akman; J S Harrison; L A Leong; Kim Margolin; Robert J Morgan; James Raschko; George Somlo; C W Ahn; James Doroshow
Pharmacokinetics and toxicity of continuous infusion (6S)-folinic acid and bolus 5-fluorouracil in patients with advanced cancer.
Cancer research 1992;52(9):2408-12.
1992: Steven Akman; James Doroshow; T G Burke; M Dizdaroglu
DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin.
Biochemistry 1992;31(13):3500-6.
1992: S K Williamson; J J Crowley; R Livingston; A Hantel; James Doroshow
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.
Investigational new drugs 1992;10(1):29-30.
1992: G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; Janice P Dutcher; E R Gaynor; D H Boldt; James Doroshow; M H Bar
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):275-81.
1992: Kim Margolin; James Doroshow; Steven Akman; L A Leong; Robert J Morgan; James Raschko; George Somlo; B Mills; D Goldberg; Irena Sniecinski
Phase I trial of interleukin-2 plus gamma-interferon.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(1):50-5.
1992: Susan G Urba; James Doroshow; C Cripps; F Robert; E Velez-Garcia; B Dallaire; D Adams; R Carlson; A Grillo-Lopez; J Gyves
Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
Cancer chemotherapy and pharmacology 1992;31(2):167-9.
1992: D Singh; James Doroshow; Lucille Leong; Kim Margolin; Steven Akman; James Raschko; George Somlo; Robert Morgan; J Harrison; J Cho
Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.
Journal of cancer research and clinical oncology 1992;119(2):117-20.
1991: Steven Akman; G P Forrest; James Doroshow; M Dizdaroglu
Mutation of potassium permanganate- and hydrogen peroxide-treated plasmid pZ189 replicating in CV-1 monkey kidney cells.
Mutation research 1991;261(2):123-30.
1991: G L Forrest; Steven Akman; James Doroshow; H Rivera; W D Kaplan
Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.
Molecular pharmacology 1991;40(4):502-7.
1991: Steven Akman; R G Lingeman; James Doroshow; Steven S Smith
Quadruplex DNA formation in a region of the tRNA gene supF associated with hydrogen peroxide mediated mutations.
Biochemistry 1991;30(35):8648-53.
1991: Kim Margolin; Frederick R Aronson; Mario Sznol; Michael B Atkins; N Ciobanu; Richard I Fisher; G R Weiss; James Doroshow; M H Bar; M J Hawkins
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):214-20.
1991: R Steven Esworthy; Fong-Fong Chu; R J Paxton; Steven Akman; James Doroshow
Characterization and partial amino acid sequence of human plasma glutathione peroxidase.
Archives of biochemistry and biophysics 1991;286(2):330-6.
1991: Matilde Maiorino; Fong-Fong Chu; Fulvio Ursini; K J Davies; James Doroshow; R Steven Esworthy
Phospholipid hydroperoxide glutathione peroxidase is the 18-kDa selenoprotein expressed in human tumor cell lines.
The Journal of biological chemistry 1991;266(12):7728-32.
1991: Janice P Dutcher; E R Gaynor; D H Boldt; James Doroshow; M H Bar; Mario Sznol; James W Mier; Joseph A Sparano; Richard I Fisher; G Weiss
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(4):641-8.
1991: T G Burke; Terry D Lee; J van Balgooy; James Doroshow
Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.
Journal of pharmaceutical sciences 1991;80(4):338-40.
1991: James Doroshow
Doxorubicin-induced cardiac toxicity.
The New England journal of medicine 1991;324(12):843-5.
1991: James Doroshow; E M Newman
Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(3):365-7.
1991: George Somlo; James Doroshow; Steven Akman; Lucille Leong; Kim Margolin; M McNamara; P Multhauf; Douglas W Blayney; R Morgan; James Raschko
Phase II study of 4'-deoxydoxorubicin (esorubicin) in advanced or metastatic adenocarcinoma of the stomach.
Investigational new drugs 1991;9(1):83-5.
1991: James Doroshow; Steven Akman; S Esworthy; Fong-Fong Chu; T Burke
Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells.
Free radical research communications 1991;12-13 Pt 2():779-81.
1991: Everett E Vokes; J W Raschko; Nicholas J Vogelzang; E E Warfield; Mark J Ratain; James Doroshow; Richard L Schilsky
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
Cancer chemotherapy and pharmacology 1991;28(1):69-73.
1990: R W Carlson; James Doroshow; O O Odujinrin; M S Flam; Mary Malec; K R Lamborn
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Investigational new drugs 1990;8(4):387-9.
1990: Kim Margolin; James Doroshow; Lucille Leong; Steven Akman; B Carr; O Odujinrin; B Flanagan; W Grove; R DeLap; D Goldberg
3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity.
Investigational new drugs 1990;8(4):369-76.
1990: Leonard A Zwelling; M L Slovak; James Doroshow; M Hinds; D Chan; E Parker; J Mayes; K L Sie; P S Meltzer; Jeffrey M. Trent
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Journal of the National Cancer Institute 1990;82(19):1553-61.
1990: Steven Akman; James Doroshow; M Dizdaroglu
Base modifications in plasmid DNA caused by potassium permanganate.
Archives of biochemistry and biophysics 1990;282(1):202-5.
1990: D R Parkinson; J S Abrams; P H Wiernik; A A Rayner; Kim Margolin; David A Van Echo; Mario Sznol; Janice P Dutcher; Frederick R Aronson; James Doroshow
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(10):1650-6.
1990: E R Gaynor; G R Weiss; Kim Margolin; Frederick R Aronson; Mario Sznol; P Demchak; K M Grima; Richard I Fisher; D H Boldt; James Doroshow
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Journal of the National Cancer Institute 1990;82(17):1397-402.
1990: G L Forrest; J Qian; J X Ma; W D Kaplan; Steven Akman; James Doroshow; S A Chen
Rat liver NAD(P)H:quinone oxidoreductase: cDNA expression and site-directed mutagenesis.
Biochemical and biophysical research communications 1990;169(3):1087-93.
1990: G L Forrest; Steven Akman; S Krutzik; R J Paxton; RS Sparkes; James Doroshow; R L Felsted; C J Glover; T Mohandas; N R Bachur
Induction of a human carbonyl reductase gene located on chromosome 21.
Biochimica et biophysica acta 1990;1048(2-3):149-55.
1990: T G Burke; M Israel; R Seshadri; James Doroshow
Abrogation of the selectivity of adriamycin for negatively-charged phospholipids by 14-valerate side chain substitution.
Cancer biochemistry biophysics 1990;11(2):177-85.
1990: Fong-Fong Chu; R Steven Esworthy; Steven Akman; James Doroshow
Modulation of glutathione peroxidase expression by selenium: effect on human MCF-7 breast cancer cell transfectants expressing a cellular glutathione peroxidase cDNA and doxorubicin-resistant MCF-7 cells.
Nucleic acids research 1990;18(6):1531-9.
1990: James Doroshow; P Multhauf; Lucille Leong; Kim Margolin; T Litchfield; Steven Akman; B Carr; M Bertrand; D Goldberg; Douglas W Blayney
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(3):491-501.
1990: Steven Akman; G Forrest; Fong-Fong Chu; R Steven Esworthy; James Doroshow
Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
Cancer research 1990;50(5):1397-402.
1990: James Doroshow; Steven Akman; Fong-Fong Chu; S Esworthy
Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones.
Pharmacology & therapeutics 1990;47(3):359-70.
1990: O Odujinrin; D Goldberg; James Doroshow; Lucille Leong; Kim Margolin; W Grove; B Carr; Steven Akman
Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
Medical and pediatric oncology 1990;18(1):49-52.
1989: Kim Margolin; James Doroshow; Lucille Leong; Steven Akman; B I Carr; O Odujinrin; B Flanagan
Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract.
American journal of clinical oncology 1989;12(6):494-7.
1989: Edward M Newman; J A Straw; James Doroshow
Pharmacokinetics of diastereoisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion.
Cancer research 1989;49(20):5755-60.
1989: K Sheibani; T Traweek; J Ben-Ezra; R Stroup; J Esteban; H Rappaport; HA Battifora; S Forman; James Doroshow; Joyce C Niland
Monocytoid B-cell lymphoma.
The American journal of surgical pathology 1989;13(10):902-4.
1989: Steven Akman; G Forrest; Fong-Fong Chu; James Doroshow
Resistance to hydrogen peroxide associated with altered catalase mRNA stability in MCF7 breast cancer cells.
Biochimica et biophysica acta 1989;1009(1):70-4.
1989: T G Burke; M Israel; R Seshadri; James Doroshow
A fluorescence study examining how 14-valerate side chain substitution modulates anthracycline binding to small unilamellar phospholipid vesicles.
Biochimica et biophysica acta 1989;982(1):123-30.
1989: David R Gandara; H Wold; E A Perez; A B Deisseroth; James Doroshow; Frederick J Meyers; K McWhirter; J Hannigan; Michael W DeGregorio
Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen.
Journal of the National Cancer Institute 1989;81(10):790-4.
1989: James Doroshow; Lucille Leong; Kim Margolin; B Flanagan; D Goldberg; M Bertrand; Steven Akman; B Carr; O Odujinrin; E Newman
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):439-44.
1989: Kim Margolin; A A Rayner; M J Hawkins; Michael B Atkins; Janice P Dutcher; Richard I Fisher; G R Weiss; James Doroshow; HS Jaffe; M Roper
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(4):486-98.
1988: K Foon; James Doroshow; E Bonnem; A Fefer; S Graham; B Grosh; P Narayan; L Elias; H Harvey; R Schulof
A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma.
Journal of biological response modifiers 1988;7(6):540-5.
1988: John M Bennett; Hyman Muss; James Doroshow; S Wolff; E T Krementz; K Cartwright; G Dukart; A Reisman; I Schoch
A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1611-20.
1988: Kim Margolin; Steven Akman; B Carr; Lucille Leong; James Doroshow
Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer.
American journal of clinical oncology 1988;11(4):499-501.
1988: Edward M Newman; James Doroshow; S J Forman; K G Blume
Pharmacokinetics of high-dose etoposide.
Clinical pharmacology and therapeutics 1988;43(5):561-4.
1988: Richard I Fisher; C A Coltman; James Doroshow; A A Rayner; M J Hawkins; James W Mier; P Wiernik; J D McMannis; G R Weiss; Kim Margolin
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.
Annals of internal medicine 1988;108(4):518-23.
1988: James Doroshow; Lucille Leong; Kim Margolin; B Flanagan; D Goldberg; M Bertrand; Steven Akman; B Carr; O Odujinrin; T Litchfield
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
Advances in experimental medicine and biology 1988;244():245-53.
1987: S C Textor; Kim Margolin; Douglas W Blayney; J Carlson; James Doroshow
Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.
The American journal of medicine 1987;83(6):1055-61.
1987: B I Carr; Douglas W Blayney; D A Goldberg; P Braly; G E Metter; James Doroshow
High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response study.
Cancer 1987;60(9):2165-9.
1987: B I Carr; Samuel Rahbar; James Doroshow; Douglas W Blayney; D Goldberg; Lucille Leong; Y Asmeron
Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.
Cancer research 1987;47(15):4199-201.
1987: R W Carlson; M E Billingham; M Kohler; F D Johnson; James Doroshow; F M Torti
Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study.
Cancer treatment reports 1987;71(4):427-8.
1987: K G Blume; Stephen J Forman; Margaret R O'Donnell; James Doroshow; Robert A Krance; Auayporn Nademanee; David S Snyder; G M Schmidt; J L Fahey; G E Metter
Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.
Blood 1987;69(4):1015-20.
1987: S A Akman; James Doroshow; M F Dietrich; R T Chlebowski; J S Block
Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210.
The Journal of pharmacology and experimental therapeutics 1987;240(2):486-91.
1987: J A Straw; Edward M Newman; James Doroshow
Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.
NCI monographs : a publication of the National Cancer Institute 1987;(5):41-5.
1987: James Doroshow; M Bertrand; E Newman; P Multhauf; Lucille Leong; Douglas W Blayney; D Goldberg; Kim Margolin; B Carr; Steven Akman
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
NCI monographs : a publication of the National Cancer Institute 1987;(5):171-4.
1986: P Braly; James Doroshow; S Hoff
Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis.
Gynecologic oncology 1986;25(3):319-33.
1986: M Bertrand; James Doroshow; P Multhauf; Douglas W Blayney; B I Carr; G Cecchi; D Goldberg; Lucille Leong; Kim Margolin; G Metter
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(7):1058-61.
1986: James Doroshow
Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(12):4514-8.
1986: Douglas W Blayney; D A Goldberg; L A Leong; B I Carr; James Doroshow
Phase II trial of esorubicin in advanced pancreatic adenocarcinoma.
Cancer treatment reports 1986;70(5):683-4.
1986: K J Davies; James Doroshow
Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.
The Journal of biological chemistry 1986;261(7):3060-7.
1986: James Doroshow; K J Davies
Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical.
The Journal of biological chemistry 1986;261(7):3068-74.
1986: James Doroshow
Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents.
Biochemical and biophysical research communications 1986;135(1):330-5.
1986: M M Kemeny; D Goldberg; J D Beatty; Douglas W Blayney; S Browning; James Doroshow; L Ganteaume; R L Hill; W A Kokal; D U Riihimaki
Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries.
Cancer 1986;57(3):492-8.
1985: M Bertrand; P Multhauf; C Presant; D Rappaport; Douglas W Blayney; B I Carr; G Cecchi; James Doroshow; E Emont; D Goldberg
Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
Cancer treatment reports 1985;69(11):1335-6.
1985: B I Carr; M Bertrand; S Browning; James Doroshow; C Presant; B Pulone; L R Hill
A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(8):1127-32.
1985: K A Margolin; H Y Pak; M L Esensten; James Doroshow
Hepatic metastasis in granulosa cell tumor of the ovary.
Cancer 1985;56(3):691-5.
1985: R N Harris; James Doroshow
Effect of doxorubicin-enhanced hydrogen peroxide and hydroxyl radical formation on calcium sequestration by cardiac sarcoplasmic reticulum.
Biochemical and biophysical research communications 1985;130(2):739-45.
1985: James Doroshow; C Tallent; J E Schechter
Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity.
The American journal of pathology 1985;118(2):288-97.
1985: J M Bennett; P Byrne; A Desai; C White; R DeConti; Charles L Vogel; E Krementz; F Muggia; James Doroshow; D Plotkin
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Investigational new drugs 1985;3(2):179-85.
1983: James Doroshow; K J Davies
Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin.
Biochemical pharmacology 1983;32(19):2935-9.
1983: James Doroshow
Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase.
Cancer research 1983;43(10):4543-51.
1983: K J Davies; James Doroshow; P Hochstein
Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin.
FEBS letters 1983;153(1):227-30.
1983: C Myers; R Bonow; S Palmeri; J Jenkins; B Corden; G Locker; James Doroshow; S Epstein
A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.
Seminars in oncology 1983;10(1 Suppl 1):53-5.
1983: James Doroshow
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Cancer research 1983;43(2):460-72.
1981: James Doroshow; G Y Locker; D E Gaasterland; S P Hubbard; R C Young; C E Myers
Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film.
Cancer 1981;48(10):2158-62.
1981: James Doroshow; G Y Locker; I Ifrim; C E Myers
Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine.
The Journal of clinical investigation 1981;68(4):1053-64.
1981: James Doroshow
Mitomycin C-enhanced superoxide and hydrogen peroxide formation in rat heart.
The Journal of pharmacology and experimental therapeutics 1981;218(1):206-11.
1981: James Doroshow; J Reeves
Daunorubicin-stimulated reactive oxygen metabolism in cardiac sarcosomes.
Biochemical pharmacology 1981;30(3):259-62.
1980: James Doroshow; G Y Locker; C E Myers
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin.
The Journal of clinical investigation 1980;65(1):128-35.
1980: James Doroshow; H Sears; C E Myers; T Anderson
Biliary colic heralding systemic relapse in non-Hodgkin lymphoma.
Journal of surgical oncology 1980;14(3):255-9.
1979: James Doroshow; G Y Locker; J Baldinger; C E Myers
The effect of doxorubicin on hepatic and cardiac glutathione.
Research communications in chemical pathology and pharmacology 1979;26(2):285-95.
1979: R F Ozols; G Y Locker; James Doroshow; K R Grotzinger; C E Myers; R C Young
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer.
Cancer research 1979;39(8):3209-14.
1979: James Doroshow; G Y Locker; C E Myers
Experimental animal models of adriamycin cardiotoxicity.
Cancer treatment reports 1979;63(5):855-60.
1979: R F Ozols; G Y Locker; James Doroshow; K R Grotzinger; C E Myers; Richard I Fisher; R C Young
Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.
Cancer treatment reports 1979;63(2):269-73.
1979: G Y Locker; James Doroshow; L A Zwelling; B A Chabner
The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature.
Medicine 1979;58(1):48-64.
1978: R A Bender; L A Zwelling; James Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Antineoplastic drugs: clinical pharmacology and therapeutic use.
Drugs 1978;16(1):46-87.
1974: J Vaage; James Doroshow; T T DuBois
Radiation-induced changes in established tumor immunity.
Cancer research 1974;34(1):129-37.